NCT03733691 - Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

October 19, 2023

Study Completion Date

October 19, 2023

Conditions

Newly Diagnosed Multiple Myeloma

Interventions

DRUG

Ixazomib

3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles

DRUG

Lenalidomide

Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.

Trial Locations (1)

James R Berenson, MD, Inc., West Hollywood